Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Life Sciences Forum (June 2026)
29 slides from Cytosorbents's conference presentation, Jun 24, 2026
Slide 1: Life Sciences Forum
NASDAQ: CTSO Life Sciences Forum June 24, 2026 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation include forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our
Slide 3: Regulatory Disclaimer
Regulatory Disclaimer CytoSorb • CE Marked in Europe for the following APPROVED Indications for Use: • Cytokine Removal • Bilirubin and Myoglobin Removal • Ticagrelor and Rivaroxaban removal during cardiothoracic surgery • CytoSorb is NOT yet cleared/approved by the FDA or Health Canada DrugSorb-ATR
Slide 4: CytoSorbents Overview
CytoSorbents Overview • U.S.-based medical device company (Nasdaq: CTSO) specializing in blood purification to treat life- threatening conditions in the intensive care unit and cardiac surgery with its proprietary, biocompatible, porous polymer bead technology • CytoSorb, the first and most studied
Slide 5: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 6: We are an Innovation Leader in Acute Care Blood Purification
We are an Innovation Leader in Acute Care Blood Purification Commercially Available Products CytoSorb ® Sepsis | Critical care | Cardiac surgery E.U., FDA EUA Ex-vivo organ perfusion for transplant E.U. Veterinarian critical care U.S. PuriFi® Hemoperfusion pump E.U. HotSwap Rapid device interchange
Slide 7: Products are “Plug and Play” Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) ECMO CPB (Extracorporeal Membrane Oxygenation) (Cardiopulmonary Bypass) 7 | CytoSorbents Confiden
Slide 8: CytoSorb
CytoSorb Our Core Business CytoSorb is E.U. CE Mark approved but not yet cleared or approved in the U.S./Canada 8 |
Slide 9: CytoSorb is Expanding the Dimension of Blood Purification
CytoSorb is Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology CE-mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It removes many substances that dialysis cannot. CytoSorb is design
Slide 10: Uncontrolled Massive Inflammation - the Heart of Critical Illness
Uncontrolled Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE SHOCK
Slide 11: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 12: CytoSorb Has Much Larger ICU Opportunity than Dialysis
CytoSorb Has Much Larger ICU Opportunity than Dialysis Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High r
Slide 13: CytoSorb Supported by a Wealth of Clinical Data
CytoSorb Supported by a Wealth of Clinical Data 13 |
Slide 14: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for Good • Treat Intensively Cinical • Compete the Full Course Outcome of Treatment Right Right Timing Dose Before After 14 |
Slide 15: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment One in 5 deaths is related to sepsis. For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broa
Slide 16: Turning the Tide of Sepsis and Septic Shock: Real World Insights
Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar-sepsis/sep10 16 |
Slide 17: The Opportunity of DrugSorb-ATR
The Opportunity of DrugSorb-ATR is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other 17 | Global Regulatory Agency and is not commercially available for sale
Slide 18: Blood Thinners and Cardiac Surgery
Blood Thinners and Cardiac Surgery • Tens of millions of patients globally take Direct Oral Anticoagulants (e.g, DOACs like Eliquis® and Xarelto®) and antiplatelet agents (e.g, Brilinta®) either chronically or acutely to reduce risk of heart attack, stroke, and other serious thrombotic complications
Slide 19: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without delay while reducing or preventing bleeding complications X X XX X 19 | DrugSorb-ATR is an investigational device in the U.S. and
Slide 20: The Pivotal STAR-T RCT Paper Is Now Published
The Pivotal STAR-T RCT Paper Is Now Published 20 | Mack, M, et al. J Thorac Cardiovasc Surg. 2026. Online ahead of print DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved
Slide 21: FDA Regulatory Update for DrugSorb-ATR and Brilinta
FDA Regulatory Update for DrugSorb-ATR and Brilinta® • FDA Appeal Decision of the original De Novo submission (August 20, 2025) • Upheld the prior denial decision based on missing primary endpoint of STAR-T pivotal trial, and required additional information primarily based on real-world evidence (RW
Slide 22: Potential Second Shot on Goal: DOAC Removal
Potential Second Shot on Goal: DOAC Removal • We have previously discussed our intention to pursue an expanded label for DrugSorb-ATR to include removal of DOACs following an initial marketing approval. Meanwhile, real-world evidence and publications continue to grow for this indication • We have no
Slide 23: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1-2 Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagr
Slide 24: Financial Performance
24 Financial Performance CytoSorbents.
Slide 25: CytoSorb Commercialization Focus
CytoSorb Commercialization Focus • We sell CytoSorb in more than 70 countries worldwide with more than 300,000 treatments to date • Sell Direct in Germany and 9 other countries & through Distributors and partners in the remainder Estimated Revenue By Market Revenue By Geography Other Critical Care:
Slide 26: A History of Strong Annual Sales Growth
A History of Strong Annual Sales Growth Q1 2026 Performance Annual Product Sales • Q1 2026 Sales were $8.9M, +2% vs $8.7M a $45.0 year ago. Trailing 12-month sales were $37.3M $39.5M $40.1M $40.0 $37.1M $37.3M • 13% growth in Direct Sales outside Germany $6.3 $9.4 $35.6M • Germany did well in midst
Slide 27: Driving to Cash Flow Breakeven in 2H 2026
Driving to Cash Flow Breakeven in 2H 2026 Negative Free Cash Flow* by Quarter Q2 2023 • Making good progress in driving improved Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 negative free cash flow through efficiency $0 development, cash management, and cos
Slide 28: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition We believe CytoSorbents is significantly undervalued and have a sound plan to build and maximize shareholder value CytoSorb is an established, international core business in critical care and cardiac surgery with $37.3M in high margin product sales (ttm) and
Slide 29: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com 29